Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase III HEEALING 1 study in severe erosive GERD. We view this as a pivotal milestone that provides clarity on the timeline and pathway to market entry of linaprazan glurate, setting the stage for significant value creation ahead.
LÄS MER
